Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 8;14(1):82.
doi: 10.3390/biom14010082.

Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury

Affiliations
Review

Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury

Nicole Nourie et al. Biomolecules. .

Abstract

Acute kidney injury (AKI) remains a complex challenge with diverse underlying pathological mechanisms and etiologies. Current detection methods predominantly rely on serum creatinine, which exhibits substantial limitations in specificity and poses the issue of late-stage detection of kidney injury. In this review, we propose an up-to-date and comprehensive summary of advancements that identified novel biomarker candidates in blood and urine and ideal criteria for AKI biomarkers such as renal injury specificity, mechanistic insight, prognostic capacity, and affordability. Recently identified biomarkers not only indicate injury location but also offer valuable insights into a range of pathological processes, encompassing reduced glomerular filtration rate, tubular function, inflammation, and adaptive response to injury. The clinical applications of AKI biomarkers are becoming extensive and serving as relevant tools in distinguishing acute tubular necrosis from other acute renal conditions. Also, these biomarkers can offer significant insights into the risk of progression to chronic kidney disease CKD and in the context of kidney transplantation. Integration of these biomarkers into clinical practice has the potential to improve early diagnosis of AKI and revolutionize the design of clinical trials, offering valuable endpoints for therapeutic interventions and enhancing patient care and outcomes.

Keywords: acute kidney injury; biomarkers; chronic kidney disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution of AKI biomarkers across the tubule. Biomarkers’ site of secretions before renal excretion (visualized by the arrows throughout the tubules) or systemic release. Locations include endothelial cells, tubular epithelial cells, interstitial cells, and podocytes.

References

    1. Califf R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018;243:213–221. doi: 10.1177/1535370217750088. - DOI - PMC - PubMed
    1. Paczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018;131:2193–2204. doi: 10.1182/blood-2018-02-791509. - DOI - PMC - PubMed
    1. De Oliveira B.D., Xu K., Shen T.H., Callahan M., Kiryluk K., D’agati V.D., Tatonetti N.P., Barasch J., Devarajan P. Molecular nephrology: Types of acute tubular injury. Nat. Rev. Nephrol. 2019;15:599–612. doi: 10.1038/s41581-019-0184-x. - DOI - PMC - PubMed
    1. Flower D.R. The lipocalin protein family: Structure and function. Biochem. J. 1996;318:1–14. doi: 10.1042/bj3180001. - DOI - PMC - PubMed
    1. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.K. The Neutrophil Lipocalin NGAL Is a Bacteriostatic Agent that Interferes with Siderophore-Mediated Iron Acquisition. Mol. Cell. 2002;10:1033–1043. doi: 10.1016/S1097-2765(02)00708-6. - DOI - PubMed